Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
TRENDS
As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
By Reiji Anasako With Takeda Pharmaceutical’s global R&D transformation making steady headway, the launch of its drug discovery joint venture, Scohia Pharma, announced on March 14 provided the industry with a clearer picture of what the company’s new Japan R&D…
To read the full story
Related Article
- Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura
March 15, 2017
- INCJ, Takeda, Medipal to Form Biotech Venture
March 14, 2017
- Takeda to Transfer Part of CMC Functions to Bushu
March 1, 2017
- Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
- Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
September 14, 2016
- Takeda to Revamp R&D Organization, Eyes Consolidated Research Sites in Japan, US
August 1, 2016
TRENDS
- Top 10 PHARMA JAPAN Articles of 2024
December 25, 2024
- Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
- Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
- 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
- Top 10 PHARMA JAPAN Articles in 2021
December 28, 2021
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…